A discrete choice experiment to understand preferences of patients with type 2 diabetes about the attributes of GLP1 receptor agonists in Spain
Patients highly valued the avoidance of injections, with weekly dosing clearly preferred over daily dosing, as well as reducing the treatment complexity. These findings may provide a better understanding of what patients prefer and value in their treatment and provide guidance for clinicians making therapeutic decisions regarding treatments of patients with type 2 diabetes.
Authors
- Miren Sequera
- Antonio Picó (ORCID: https://orcid.org/0000-0002-7549-7563)
- Patricia San José (ORCID: https://orcid.org/0000-0002-1884-3554)
- Ana Monteagudo (ORCID: https://orcid.org/0000-0001-7000-4582)
- Jesús Medina
Institutions
- Universitat de Miguel Hernández d'Elx (ES)
- Bellvitge University Hospital (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES)
- AstraZeneca (France) (FR)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Switzerland) (CH)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
- Hospital General de Elda (ES)
- AstraZeneca (Spain) (ES)
- Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) (ES)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1080/03007995.2024.2407960
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca